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In the mid ‘90s tremendous progress has marked the
pharmacological approach to HIV-1 disease, resulting in
the almost complete reversal of the “death sentence” that
was associated with the diagnosis of HIV infection and
AIDS. However, the terrific advantages of combination
antiretroviral therapy (cART) are not available homoge-
neously on a global scale, with the number of individuals
becoming infected still outscoring that of infected people
starting treatment. Even restricting the analysis to those
countries, including Europe, where cART is largely avail-
able, there are several considerations supporting the con-
cept that therapy suspension could still be considered in
specific settings, and not only for facing the management
of accumulation of multidrug resistant viral species or
therapy-related side effects. In fact, some of the most
novel and exciting novelties in the field of HIV research
have arisen from examples of either casual or pro-
grammed therapy suspension. In the case of the so-called
“Mississippi Baby”, a newborn (from a mother with
undiagnosed AIDS until the time of delivery) was treated
with cART shortly after delivery; nonetheless, she became
unequivocally infected, but seroreverted after a few
weeks. Later, cART was suspended for unknown reasons,
surprisingly resulting in the lack of virus rebound and
HIV detectability by multiple testing, leading to the
hypothesis that she might represent the second case of
“cure” after Tymothy Ray Brown, the “Berlin patient”. In
a second example, adult French patients who started
their antiretroviral regimens very early after primary HIV
infection, underwent therapy suspension after a few years
resulting in an unexpected high frequency of sponta-
neous control of HIV-1 viremia and disease progression
(Post-therapy controllers, or VISCONTI cohort). The
likelihood that they might represent conventional sponta-
neous controllers of disease progression, such as LTNP
or Elite controllers, is minimal in that their genetic pro-
file is enriched in the BW35 MHC allele that is counter-
selected in these categories. In summary, without these
and other example of cART suspension our current
understanding of the potential opportunities to tilt the
balance in favor of the host rather than of the virus
would be more limited and perhaps would prevent future
strategic approaches to achieve long-term control of HIV
infection with minimal side effects related to cART.
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